Rodent models and metabolomics in non-alcoholic fatty liver disease: What can we learn?
- PMID: 35317178
- PMCID: PMC8891675
- DOI: 10.4254/wjh.v14.i2.304
Rodent models and metabolomics in non-alcoholic fatty liver disease: What can we learn?
Abstract
Non-alcoholic fatty liver disease (NAFLD) prevalence has increased drastically in recent decades, affecting up to 25% of the world's population. NAFLD is a spectrum of different diseases that starts with asymptomatic steatosis and continues with development of an inflammatory response called steatohepatitis, which can progress to fibrosis. Several molecular and metabolic changes are required for the hepatocyte to finally vary its function; hence a "multiple hit" hypothesis seems a more accurate proposal. Previous studies and current knowledge suggest that in most cases, NAFLD initiates and progresses through most of nine hallmarks of the disease, although the triggers and mechanisms for these can vary widely. The use of animal models remains crucial for understanding the disease and for developing tools based on biological knowledge. Among certain requirements to be met, a good model must imitate certain aspects of the human NAFLD disorder, be reliable and reproducible, have low mortality, and be compatible with a simple and feasible method. Metabolism studies in these models provides a direct reflection of the workings of the cell and may be a useful approach to better understand the initiation and progression of the disease. Metabolomics seems a valid tool for studying metabolic pathways and crosstalk between organs affected in animal models of NAFLD and for the discovery and validation of relevant biomarkers with biological understanding. In this review, we provide a brief introduction to NAFLD hallmarks, the five groups of animal models available for studying NAFLD and the potential role of metabolomics in the study of experimental NAFLD.
Keywords: Biomarkers; Liver disease; Metabolic profiling; Metabolomics; Non-alcoholic fatty liver disease; Rodent models.
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: Authors have nothing to disclose.
Figures

Similar articles
-
Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances.J Pathol. 2017 Jan;241(1):36-44. doi: 10.1002/path.4829. Epub 2016 Nov 22. J Pathol. 2017. PMID: 27757953 Free PMC article. Review.
-
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.Metabolomics. 2021 Jan 16;17(2):12. doi: 10.1007/s11306-020-01756-1. Metabolomics. 2021. PMID: 33458794
-
From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.Proc Nutr Soc. 2019 Aug;78(3):290-304. doi: 10.1017/S0029665119000570. Epub 2019 Mar 29. Proc Nutr Soc. 2019. PMID: 30924429 Review.
-
Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.Clin Ther. 2021 Sep;43(9):1505-1522. doi: 10.1016/j.clinthera.2021.07.012. Epub 2021 Aug 13. Clin Ther. 2021. PMID: 34400007 Review.
-
A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet.Molecules. 2022 Jan 27;27(3):858. doi: 10.3390/molecules27030858. Molecules. 2022. PMID: 35164140 Free PMC article. Review.
Cited by
-
2D-DIGE Proteomic Analysis of Mouse Liver Within 1 Week.Methods Mol Biol. 2023;2596:217-230. doi: 10.1007/978-1-0716-2831-7_16. Methods Mol Biol. 2023. PMID: 36378442
-
Microbiota Co-Metabolism Alterations Precede Changes in the Host Metabolism in the Early Stages of Diet-Induced MASLD in Wistar Rats.Int J Mol Sci. 2025 Feb 2;26(3):1288. doi: 10.3390/ijms26031288. Int J Mol Sci. 2025. PMID: 39941056 Free PMC article.
-
Pharmacokinetic Effects of Different Models of Nonalcoholic Fatty Liver Disease in Transgenic Humanized OATP1B Mice.Drug Metab Dispos. 2024 Apr 16;52(5):355-367. doi: 10.1124/dmd.123.001607. Drug Metab Dispos. 2024. PMID: 38485280 Free PMC article.
References
-
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. - PubMed
-
- Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. - PubMed
-
- Araújo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future. Liver Int. 2018;38 Suppl 1:47–51. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous